A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

To be considered for this study, you must be at least 18 years old and have extensive-stage small cell lung cancer that has been confirmed by a doctor. This means your cancer has spread, and it must have either come back or not responded to at least one previous treatment that included a type of chemotherapy called platinum-based chemotherapy. You will also need to provide a sample of your tumour tissue, either an existing one or a new biopsy. If you have HIV, you can still participate as long as your HIV is well-controlled with medication.

There are several reasons why you might not be able to join this study. For example, if you have fluid build-up around your lungs, heart, or in your belly that needs frequent draining. You also can't join if you have certain lung conditions, like a history of serious lung inflammation, or severe breathing difficulties from other illnesses. Recent heart problems, such as a heart attack, serious heart failure, or uncontrolled irregular heartbeats within the last six months, would also prevent you from taking part.

Other reasons you might not be eligible include a recent blood clot in your brain (stroke or mini-stroke), active infections that need strong medication, a history of an organ transplant, or cancer that has spread to the lining of your brain and spinal cord. If you've had recent radiation therapy or are taking high doses of steroid medication or other medicines that suppress your immune system, you also wouldn't be able to join the study.

If you join this study, you will receive either Gocatamig, Ifinatamab Deruxtecan, or a combination of Gocatamig and Durvalumab. The specific treatment you receive will be decided by the study doctors. You will have regular visits to the hospital or clinic, which will include physical examinations, blood tests, and scans (like CT scans) to see how the treatment is working and check for any side effects. You'll also be asked about your general health and any symptoms you might be experiencing. These visits will help the research team carefully monitor your health and the progress of your cancer. The total length of your participation will depend on how you respond to the treatment and the study plan, but there will also be follow-up appointments after you finish your treatment.